Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 118

1.

CyberKnife® M6™: Peripheral dose evaluation for brain treatments.

Delaby N, Bellec J, Bouvier J, Jouyaux F, Perdrieux M, Castelli J, Lecouillard I, Manens JP, Lafond C.

Phys Med. 2017 May;37:88-96. doi: 10.1016/j.ejmp.2017.04.015. Epub 2017 May 9.

PMID:
28535920
2.

Metabolic Tumor Volume and Total Lesion Glycolysis in Oropharyngeal Cancer Treated With Definitive Radiotherapy: Which Threshold Is the Best Predictor of Local Control?

Castelli J, Depeursinge A, de Bari B, Devillers A, de Crevoisier R, Bourhis J, Prior JO.

Clin Nucl Med. 2017 Jun;42(6):e281-e285. doi: 10.1097/RLU.0000000000001614.

PMID:
28288042
3.

The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership.

Chajon E, Castelli J, Marsiglia H, De Crevoisier R.

Crit Rev Oncol Hematol. 2017 Mar;111:124-132. doi: 10.1016/j.critrevonc.2017.01.017. Epub 2017 Feb 4. Review.

PMID:
28259287
4.

Is Dose Deformation-Invariance Hypothesis Verified in Prostate IGRT?

Simon A, Le Maitre A, Nassef M, Rigaud B, Castelli J, Acosta O, Haigron P, Lafond C, de Crevoisier R.

Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):830-838. doi: 10.1016/j.ijrobp.2016.12.011. Epub 2016 Dec 12.

PMID:
28244420
5.

A PET-based nomogram for oropharyngeal cancers.

Castelli J, Depeursinge A, Ndoh V, Prior JO, Ozsahin M, Devillers A, Bouchaab H, Chajon E, de Crevoisier R, Scher N, Jegoux F, Laguerre B, De Bari B, Bourhis J.

Eur J Cancer. 2017 Apr;75:222-230. doi: 10.1016/j.ejca.2017.01.018. Epub 2017 Feb 24.

PMID:
28237868
6.

The benefit of using bladder sub-volume equivalent uniform dose constraints in prostate intensity-modulated radiotherapy planning.

Zhu J, Simon A, Haigron P, Lafond C, Acosta O, Shu H, Castelli J, Li B, De Crevoisier R.

Onco Targets Ther. 2016 Dec 12;9:7537-7544. doi: 10.2147/OTT.S116508. eCollection 2016.

7.

Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy.

Castelli J, De Bari B, Depeursinge A, Simon A, Devillers A, Roman Jimenez G, Prior J, Ozsahin M, de Crevoisier R, Bourhis J.

Crit Rev Oncol Hematol. 2016 Dec;108:40-51. doi: 10.1016/j.critrevonc.2016.10.009. Epub 2016 Oct 29. Review.

PMID:
27931839
8.

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.

Hughes DA, Nicholls K, Shankar SP, Sunder-Plassmann G, Koeller D, Nedd K, Vockley G, Hamazaki T, Lachmann R, Ohashi T, Olivotto I, Sakai N, Deegan P, Dimmock D, Eyskens F, Germain DP, Goker-Alpan O, Hachulla E, Jovanovic A, Lourenco CM, Narita I, Thomas M, Wilcox WR, Bichet DG, Schiffmann R, Ludington E, Viereck C, Kirk J, Yu J, Johnson F, Boudes P, Benjamin ER, Lockhart DJ, Barlow C, Skuban N, Castelli JP, Barth J, Feldt-Rasmussen U.

J Med Genet. 2017 Apr;54(4):288-296. doi: 10.1136/jmedgenet-2016-104178. Epub 2016 Nov 10.

9.

Sudden death in infective endocarditis.

Castelli JB, Almeida G, Siciliano RF.

Autops Case Rep. 2016 Sep 30;6(3):17-22. eCollection 2016 Jul-Sep.

10.

The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat.

Benjamin ER, Della Valle MC, Wu X, Katz E, Pruthi F, Bond S, Bronfin B, Williams H, Yu J, Bichet DG, Germain DP, Giugliani R, Hughes D, Schiffmann R, Wilcox WR, Desnick RJ, Kirk J, Barth J, Barlow C, Valenzano KJ, Castelli J, Lockhart DJ.

Genet Med. 2017 Apr;19(4):430-438. doi: 10.1038/gim.2016.122. Epub 2016 Sep 22.

11.

[Clinical to planning target volume margins in prostate cancer radiotherapy].

Ramiandrisoa F, Duvergé L, Castelli J, Nguyen TD, Servagi-Vernat S, de Crevoisier R.

Cancer Radiother. 2016 Oct;20(6-7):629-39. doi: 10.1016/j.canrad.2016.07.095. Epub 2016 Sep 7. Review. French.

PMID:
27614515
12.

[Interest of positioning control in onboard imaging and its delegation to the therapists].

de Crevoisier R, Duvergé L, Hulot C, Chauvet B, Henry O, Bouvet C, Castelli J.

Cancer Radiother. 2016 Oct;20(6-7):601-7. doi: 10.1016/j.canrad.2016.07.084. Epub 2016 Sep 7. Review. French.

PMID:
27614503
13.

Pre- and per-treatment 18F-FDG PET/CT parameters to predict recurrence and survival in cervical cancer.

Leseur J, Roman-Jimenez G, Devillers A, Ospina-Arango JD, Williaume D, Castelli J, Terve P, Lavoue V, Garin E, Lejeune F, Acosta O, De Crevoisier R.

Radiother Oncol. 2016 Sep;120(3):512-518. doi: 10.1016/j.radonc.2016.08.008. Epub 2016 Aug 25.

PMID:
27569847
14.

Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.

Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, Feliciani C, Shankar SP, Ezgu F, Amartino H, Bratkovic D, Feldt-Rasmussen U, Nedd K, Sharaf El Din U, Lourenco CM, Banikazemi M, Charrow J, Dasouki M, Finegold D, Giraldo P, Goker-Alpan O, Longo N, Scott CR, Torra R, Tuffaha A, Jovanovic A, Waldek S, Packman S, Ludington E, Viereck C, Kirk J, Yu J, Benjamin ER, Johnson F, Lockhart DJ, Skuban N, Castelli J, Barth J, Barlow C, Schiffmann R.

N Engl J Med. 2016 Aug 11;375(6):545-55. doi: 10.1056/NEJMoa1510198.

15.

Optimal adaptive IMRT strategy to spare the parotid glands in oropharyngeal cancer.

Zhang P, Simon A, Rigaud B, Castelli J, Ospina Arango JD, Nassef M, Henry O, Zhu J, Haigron P, Li B, Shu H, De Crevoisier R.

Radiother Oncol. 2016 Jul;120(1):41-7. doi: 10.1016/j.radonc.2016.05.028. Epub 2016 Jun 29.

PMID:
27372223
16.

[Expected benefit of lymph node and seminal vesical dissection to decrease high-risk prostate cancer radiotherapy].

Colliaux J, Kharchi L, Vincendeau S, Simon A, Perdrieux M, Le Prisé É, Bellisant É, Castelli J, de Crevoisier R.

Cancer Radiother. 2016 Jul;20(5):347-56. doi: 10.1016/j.canrad.2016.04.006. Epub 2016 Jun 22. French.

PMID:
27344535
17.

A Nomogram to predict parotid gland overdose in head and neck IMRT.

Castelli J, Simon A, Rigaud B, Lafond C, Chajon E, Ospina JD, Haigron P, Laguerre B, Loubière AR, Benezery K, de Crevoisier R.

Radiat Oncol. 2016 Jun 8;11:79. doi: 10.1186/s13014-016-0650-6.

18.

Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series.

Castelli J, Feuvret L, Haoming QC, Biau J, Jouglar E, Berger A, Truc G, Gutierrez FL, Morandi X, Le Reste PJ, Thillays F, Loussouarn D, Nouhaud E, Crehange G, Antoni D, Vauleon E, de Crevoisier R, Noel G.

J Neurooncol. 2016 Aug;129(1):85-92. doi: 10.1007/s11060-016-2142-9. Epub 2016 May 11.

PMID:
27169763
19.

Prepare, Do, Review: A skills-based approach for laboratory practical classes in biochemistry and molecular biology.

Arthur P, Ludwig M, Castelli J, Kirkwood P, Attwood P.

Biochem Mol Biol Educ. 2016 May 6;44(3):276-87. doi: 10.1002/bmb.20951.

PMID:
27161811
20.

Impact of a Multimodal Approach in Prevention of Surgical Site Infection in Hepatic Transplant Recipients.

Prieto J, Medina JC, López M, Rando K, Iglesias C, Harguindeguy M, Leites A, Etlin A, Menéndez J, Valverde M, Scalone P, Castelli J, Grecco G, Abelleira M, González LS, Gerona S.

Transplant Proc. 2016 Mar;48(2):658-64. doi: 10.1016/j.transproceed.2016.02.032.

PMID:
27110024

Supplemental Content

Loading ...
Support Center